Navigation Links
Availity Engages Prematics to Deploy Electronic Prescribing
Date:2/26/2008

Initial Deployment Includes Physician Practices in Florida and Texas

JACKSONVILLE, Fla. and BETHESDA, Md., Feb. 26 /PRNewswire/ -- Availity, L.L.C. and Prematics(TM) today announced an agreement to equip physician practices with a distinctive electronic prescribing service under Availity's private label, CarePrescribe(SM). Prematics will deploy its technology and provide ongoing physician support on behalf of Availity and its joint ownership group, consisting of Blue Cross and Blue Shield of Florida, Humana, and Health Care Service Corporation, which operates the Blue Cross and Blue Shield plans in Illinois, New Mexico, Oklahoma, and Texas. Initial deployment will include markets in Florida and Texas.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070315/CLTH096LOGO )

A leading provider of e-health transaction services, Availity optimizes information between multiple health care stakeholders through a single, secure exchange on a regional basis. Administrative, clinical, and financial services are available through a single, secure online portal -- the Availity(R) Health Information Network -- enabling physicians and providers to remove administrative inefficiencies, reduce costs, and improve the patient experience.

Availity will add CarePrescribe to its existing suite of products available on its secure provider Web portal. As a result, participating physicians will have access to important patient-specific formulary, eligibility, and medication history at the point of care for all patients, regardless of coverage, as well as the ability to transmit prescriptions electronically to the patient's pharmacy of choice. Prematics will also provide eligible physicians with installation of dedicated wireless handheld devices and high-speed connectivity as well as training and support. All aspects of CarePrescribe will be provided at no cost to the physician
'/>"/>

SOURCE Prematics; Availity, L.L.C.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. MiddleBrook Pharmaceuticals Engages Morgan Stanley in Its Strategic Process
2. Roche Engages in Four Additional AIDS Technology Transfers to Strengthen Local Manufacturing in Worlds Poorest Countries
3. LTC Financial Partners (LTCFP) Engages CareScout to Bring Comprehensive Long Term Care Solutions to LTCFP Clients; A One-Stop Shop for All Care Information - An Industry First
4. Dana-Farber Cancer Institute Completes Deployment of MedAptus Infusion Services Module
5. UT Southwestern plastic surgeons deploy new carbon dioxide-based fractional laser
6. Harman/Becker Automotive Systems Completes Initial Deployments of Visiprise Integrated Manufacturing Execution
7. Peninsula United Methodist Homes Completes Enterprise-Wide Deployment of AccuNurse Voice-Assisted Care
8. CoxHealth Deploys Kryptiq ePrescribing Solution
9. Easter Seals Launches Nationwide Program for U.S. Service Members and Veterans Deployed to Iraq or Afghanistan with Traumatic Brain Injury
10. How do multiple deployments affect soldiers and their families?
11. Cardiac Science Wins Major Corporate AED Deployment Contracts
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 2ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 3ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 4ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 5ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 6ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 7Trubion and Facet Biotech Announce Presentation of Positive TRU-016 Data at the 2009 ASH Annual Meeting 2Trubion and Facet Biotech Announce Presentation of Positive TRU-016 Data at the 2009 ASH Annual Meeting 3Trubion and Facet Biotech Announce Presentation of Positive TRU-016 Data at the 2009 ASH Annual Meeting 4Trubion and Facet Biotech Announce Presentation of Positive TRU-016 Data at the 2009 ASH Annual Meeting 5Trubion and Facet Biotech Announce Presentation of Positive TRU-016 Data at the 2009 ASH Annual Meeting 6FDA Makes Interim Recommendations to Address Concern of Excess Radiation Exposure during CT Perfusion Imaging 2FDA Makes Interim Recommendations to Address Concern of Excess Radiation Exposure during CT Perfusion Imaging 3aTyr Pharma to Present at Japan Biopharma Partnering Conference 58295 1aTyr Pharma to Present at Japan Biopharma Partnering Conference 58295 2Free Wheelchair Mission Listed by Ministry Watch as Top 30 Shining Light Exemplary Ministry for 2008 58293 1Free Wheelchair Mission Listed by Ministry Watch as Top 30 Shining Light Exemplary Ministry for 2008 58293 2Virginia Now Owns Three Top National Business Rankings 14267 1Virginia Now Owns Three Top National Business Rankings 14267 2